Fetal transplantation for the treatment of neurodegenerative diseases. Current status and future potential

CNS Drugs

Volumn 9, Issue 2, 1998, Pages 77-83

  Kopyov, Oleg V ^a   Jacques, Skip ^a   Eagle, Kaaren S ^a  

^a GOOD SAMARITAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROTROPHIC FACTOR;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE COURSE; DRUG INFUSION; FETAL TISSUE TRANSPLANTATION; GENE TRANSFER; HUMAN; HUNTINGTON CHOREA; MOTOR ACTIVITY; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0031911854     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199809020-00001     Document Type: Review

References (78)

1. Lindvall O, Bjorklund A. Transplantation strategies in the treatment of Parkinson's disease: experimental basis and clinical trials. Acta Neurol Scand Suppl 1989; 126: 197-210
2. Sinden JD, Patel SN, Hodges H. Neural transplantation: problems and prospects for therapeutic application. Curr Opin Neurol Neurosurg 1992 Dec; 5 (6): 902-8
3. Borlongan CV, Cahill DW, Freeman TB, et al. Recent advances in neural transplantation: relevance to neurodegenerative disorders. J Fla Med Assoc 1994; 81 (10): 689-94
4. Dunnett SB, Bjorklund A. Functional neural transplantation. New York: Raven Press, 1994
5. Eadie MJ. The neuropathology of Parkinson's disease. Aust NZ J Med 1971 May; I Suppl. 1: 7-13
6. Steg G. Pathological aspects of Parkinson's syndrome. Acta Neurol Scand Suppl 1972; 51: 139-50
7. Brundin P, Strecker RE, Clarke DJ. et al. Can human fetal dopamine neuron grafts provide a therapy for Parkinson's disease? Prog Brain Res 1988; 78: 441-8
8. Bruyn GW. Huntington's chorea: historical, clinical and laboratory synopsis. In: Vinken PJ, Bruyn EW, editors. Handbook of clinical neurology. Vol. 6. Diseases of the basal ganglia. Amsterdam: North-Holland Publishing Co., 1968: 298-378
9. Vonsattel JP, Myers RH, Stevens TJ, et al. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44 (6): 559-77
10. Hoffer B, Olson L. Treatment strategies for neurodegenerative diseases based on trophic factors and cell transplantation techniques. J Neural Transm Suppl 1997; 49: 1-10
11. Rosenfeld JV. Current issues in neural transplantation. Ann Acad Med Singapore 1993; 22 (3): 464-9
12. Boulton AA, Baker GB, Butterworth RF, editors. Animal models of neurological disease. Totowa (NJ): Humana Press, 1992
13. Schwarting RK, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 1996; 50 (2-3): 275-331
14. Sanberg PR, Koutouzis TK, Freeman TB, et al. Behavioral effects of fetal neural transplants: relevance to Huntington's disease. Brain Res Bull 1993; 32 (5): 493-6
15. Emerich EF, Ragozzino MR, Lehman MN, et al. Behavioral effects of neural transplantation. Cell Transplant 1992; 1 (6): 401-27
16. Annett LE, Martol FL, Rogers DC, et al. Behavioral assessment of the effects of embryonic nigral grafts in marmosets with unilateral 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 1994; 125 (2): 228-46
17. Anett LE. Functional studies of neural grafts in parkinsonian primates. In: Dunnett SB, Bjorklund A, editors. Functional neural transplantation. New York: Raven Press, 1994; 71-102
18. Dunnett S. Cholinergic grafts, memory and aging. Trends Neurosci 1991; 14: 371-6
19. Zhou FC, Buchwald N. Connectivities of the striatal grafts in adult rat brain: a rich afference and scant striatonigral efference. Brain Res 1989; 505 (1): 15-30
20. Wictorin K, Simerly RB, Isacson O, et al. Connectivity of striatal grafts implanted into the ibotenic acid-lesioned striatum. III. Efferent projecting graft neurons and their relation to host afferents within the grafts. Neuroscience 1989; 29 (3): 313-30
21. Xu ZC, Wilson CJ, Emson PC. Restoration of the corticostriatal projection in rat neostriatal grafts: electron microscopic analysis. Neuroscience 1989; 29 (3): 539-50
22. Xu ZC, Wilson CJ, Emson PC. Restoration of thalamostriatal projections in rat neostriatal grafts: an electron microscopic analysis. J Comp Neurol 1991; 303 (1): 22-34
23. Xu ZC, Wilson CJ, Emson PC. Synaptic potentials evoked in spiny neurons in rat neostriatal grafts by cortical and thalamic stimulation. J Neurophysiol 1991; 65 (3): 477-93
24. Walsh JP, Zhou FC, Hull CD, et al. Physiological and morphological characterization of striatal neurons transplanted into the striatum of adult rats. Synapse 1988; 2 (1): 37-44
25. van Horne C, Mahalik T, Hoffer B, et al. Behavioral and electrophysiological correlates of human mesencephalic dopaminergic xenograft function in the rat striatum. Brain Res Bull 1990; 25: 325-34
26. Rioux L, Gaudin DP, Bui LK, et al. Correlation of functional recovery after a 6-hydroxydopamine lesion with survival of grafted fetal neurons and release of dopamine in the striatum of the rat. Neuroscience 1991; 40: 123-31
27. Earl CD, Reum T, Xie JX, et al. Foetal nigral cell suspension grafts influence dopamine release in the non-grafted side in the 6-hydroxydopamine rat model of Parkinson's disease: in vivo voltammetric data. Exp Brain Res 1996 Apr; 109 (1): 179-84
28. Lindvall O, Rehncrona S, Brundin P, et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease: a detailed account of methodology and a 6-month follow-up. Arch Neurol 1989; 46 (6): 615-31
29. Spencer DD, Robbins RJ, Naftolin F, et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med 1992; 327 (22): 1541-8
30. Freed CR, Breeze RE, Rosenberg NL, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med 1992; 327 (22): 1549-55
31. Lindvall O, Sawle G, Widner H, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994; 35 (2): 172-80
32. Wenning GK, Odin P, Morrish BM, et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 1997; 42: 95-107
33. Freeman TB, Olanow CW, Hauser RA, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 1995; 38 (3): 379-88
34. Kopyov OV, Jacques D, Lieberman A, et al. Clinical study of fetal mesencephalic intracerebral transplants for the treatment of Parkinson's disease. Cell Transplant 1996; 5 (2): 327-37
35. Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 1996; 19: 102-9
36. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992; 7 (1): 2-13
37. Peschanski M, Cesaro P, Hantraye P. Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease Neuroscience 1995; 68 (2): 273-85
38. Shannon KM, Kordower JH. Neural transplantation for Huntington's disease: experimental rationale and recommendations for clinical trials. Cell Transplant 1996; 5 (2): 339-52
39. Kopyov OV, Jacques DS, Lieberman A, et al. Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp Neurol. In press
40. Philpolt LM, Kopyov OV, Lec AJ, et al. Neuropsychological functioning following fetal striatal transplantation in Huntington's chorea: three case presentations. Cell Transplant 1997; 6 (3): 203-12
41. Quinn N, Brown R, Craufurd D, et al. Core Assessment Program for Intracerebral Transplantation in Huntington's Disease (CAPIT-HD). Mov Disord 1996; 11 (2): 143-50
42. Kopyov OV, Jacques DS, Lieberman A, et al. Outcome following intrastriatal fetal mesencephalic grafts for Parkinson's patients is directly related to the volume of grafted tissue. Exp Neurol 1997; 146 (2): 536-45
43. Nikkhah G, Odin P, Smits A, et al. Platelet-derived growth factor promotes survival of rat and human mesencephalic dopaminergic neurons in culture. Exp Brain Res 1993; 92 (3): 516-23
44. Nikkhah G, Bentlage C, Cunningham MG, et al. Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson model. J Neurosci 1994; 14 (6): 3449-61
45. Heim RC, Willingham G, Freed WJ. A comparison of solid intraventricular and dissociated intraparenchymal fetal substantia nigra gratis in a rat model of Parkinson's disease: impaired graft survival is associated with high baseline rotational behavior. Exp Neurol 1993; 122 (1): 5-15
46. Hefti F. Pharmacology of neurotrophic factors. Annu Rev Pharmacol Toxicol 1997; 37: 239-67
47. Bartus RT, Dean RL, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217 (4558): 408-14
48. Knusel B, Gao H. Neurotrophins and Alzheimer's disease: beyond the cholinergic neurons. Life Sci 1996; 58 (22): 2019-27
49. Koliatsos VE. Biological therapies for Alzheimer's disease: focus on trophic factors. Crit Rev Neurobiol 1996; 10 (2): 205-38
50. Weinstock M. The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: an update. Neurodegeneration 1995; 4 (4): 349-56
51. Lapchak PA, Gash DM, Jiao S, et al. Glial cell line-derived neurotrophic factor: a novel therapeutic approach to treat motor dysfunction in Parkinson's disease. Exp Neurol 1997; 144 (1): 29-34
52. Clarkson ED, Zawada WM, Freed CR. GDNP improves survival and reduces apoptosis in human embryonic dopaminergic neurons in vitro. Cell Tissue Res 1997; 289 (2): 207-10
53. Rosenblad C, Martinez-Serrano A, Bjorklund A. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience 1996; 75 (4): 979-85
54. Granholm AC, Mott JL, Bowenkamp K, et al. Glial cell line-derived neurotrophic factor improves survival of ventral mesencephalic grafts to the 6-hydroxydopamine lesioned striatum. Exp Brain Res 1997; 116 (1): 29-38
55. Lapchak PA, Gash DM, Collins F, et al. Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): preclinical development and application to the treatment of Parkinson's disease. Exp Neurol 1997; 145 (2 Pt 1): 309-21
56. Zurn AD, Baetge EE, Hammang JP, et al. Glial cell line-derived neurotrophic factor (GDNF), a new neurotrophic factor for motorneurones. Neuroreport 1994 Dec; 6 (1): 113-8
57. Wang Y, Tien LT, Lapchak PA, et al. GDNF triggers fiber outgrowth of fetal ventral mesencephalic grafts from nigra to striatum in 6-OHDA-lesioned rats. Cell Tissue Res 1996; 286 (2): 225-33
58. Lapchak PA, Miller PJ, Collins F, et al. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery. Neuroscience 1997; 78 (1): 61-72
59. Anderson KD, Panayotatos N, Corcoran TL, et al. Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington's disease. Proc Natl Acad Sci USA 1996; 93 (14): 7346-51
60. Emerich DF, Cain CK, Greco C, et al. Cellular delivery of human CNTF prevents motor and cognitive dysfunction in a rodent model of Huntington's disease. Cell Transplant 1997; 6 (3): 249-66
61. Seiger A, Nordberg A, von Holst H, et al. Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy. Behav Brain Res 1993 Nov; 57 (2): 255-61
62. Van Horne C, Stromberg I, Young D, et al. Functional enhancement of intrastriatal dopamine-containing grafts by the co-transplantation of sciatic nerve tissue in 6-hydroxydopamine-lesioned rats. Exp Neurol 1991; 113 (2): 143-54
63. Collier TJ, Elsworth JD, Taylor JR, et al. Peripheral nerve-dopamine neuron co-grafts in MPTP-treated monkeys: augmentation of tyrosine hydroxylase-positive fiber staining and dopamine content in host systems. Neuroscience 1994; 61 (4): 875-89
64. Schinstine M, Fiore DM, Winn SR, et al. Polymer-encapsulated Schwannoma cells expressing human nerve growth factor promote the survival of cholinergic neurons after a fimbria-fornix transection. Cell Transplant 1995 Jan-Feb; 4 (1): 93-102
65. Date I, Miyoshi Y, Ono T, et al. Preliminary report of polymer-encapsulated dopamine-secreting cell grafting into the brain. Cell Transplant 1996; 5 (5 Suppl. 1): S17-9
66. Emerich DF, Winn SR, Hantraye PM, et al. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature 1997; 386 (6623): 395-9
67. Raymon HK, Thode S, Gage FH. Application of ex vivo gene therapy in the treatment of Parkinson's disease. Exp Neurol 1997; 144 (1): 82-91
68. Blesch A, Tuszynski M. Ex vivo gene therapy for Alzheimer's disease and spinal cord injury. Clin Neurosci 1995; 3 (5): 268-74
69. Yamada K, Nitta A, Hasegawa T, et al. Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease. Behav Brain Res 1997; 83 (1-2): 117-22
70. Albeck DS, Hoffer BJ, Quissell D, et al. A non-invasive transport system for GDNF across the blood-brain barrier. Neuroreport 1997; 8 (9-10): 2293-8
71. Horellou P, Sahate O, Buc-Caron MH, et al. Adenovirus-mediated gene transfer to the central nervous system for Parkinson's disease. Exp Neurol 1997; 144 (1): 131-8
72. Freeman TB. From transplants to gene therapy for Parkinson's disease. Exp Neurol 1997; 144 (1): 47-50
73. Shvaloff A, Neuman E, Guez D. Lines of therapeutics research in Alzheimer's disease. Psychopharmacol Bull 1996; 32 (3): 343-52
74. Sanders LM, Giudice L, Raffin TA. Ethics of fetal tissue transplantation. West J Med 1993; 159 (3): 400-7
75. Fine A. Human fetal tissue research: practice, prospects, and policy. Cell Transplant 1994; 3 (2): 113-45
76. MacDonald AS. Foetal neuroendocrine tissue transplantation for Parkinson's disease: an institutional review board faces the ethical dilemma. Transplant Proc 1990; 22 (3): 1030-2
77. Boer GJ. Ethical guidelines for the use of human embryonic or fetal tissue for experimental and clinical neurotransplantation and research. Network of European CNS Transplantation and Restoration (NECTAR). J Neurol 1994; 242 (1): 1-13
78. Kirschstein RL. Withdrawal of interim NIH guidelines for the support and conduct of therapeutic human fetal tissue transplantation research in light of superseding provisions of Public Law 103-43. Fed Regist 1993; 58 (166): 45495-6